Novocure (NSDQ:NVCR) today released results from the Stellar phase 2 registration trial exploring the use of its Tumor Treating Fields and standard of care chemotherapy to chemotherapy alone in treating mesothelioma, touting a significant extension in median overall survival.
Patients with malignant pleural mesothelioma who received TTF treatment alongside pemetrexed and cisplatin or carboplatin experienced a median overall survival of 18.2 months, compared to 12.1 months in a historical control, the St. Helier, Jersey-based company said.
Read the whole story on our sister site, Drug Delivery Business News
The post Novocure touts combined TTF, chemotherapy mesothelioma study data appeared first on MassDevice.
from MassDevice https://ift.tt/2M1BqL3
Cap comentari:
Publica un comentari a l'entrada